JCR Pharmaceuticals Presents Promising Blood-Brain Barrier Data for Rare Disease Therapies at WORLDSymposium 2026
核心洞察
JCR Pharmaceuticals (搜索) presented four datasets at WORLDSymposium 2026 demonstrating the potential of its J-Brain Cargo® blood-brain barrier-penetrating technology for treating lysosomal storage disorders (搜索).
Preclinical data for JR-471 showed over 95% reduction in accumulated substrates in brain and peripheral tissues in a fucosidosis (搜索) mouse model, with preserved motor function and prevention of Purkinje cell loss.
Long-term clinical data for pabinafusp alfa (IZCARGO™) in Hunter syndrome (搜索) patients showed sustained cognitive improvements and somatic benefits across diverse age groups and disease phenotypes.
JCR Pharmaceuticals (搜索) Co., Ltd. showcased compelling evidence for its blood-brain barrier-penetrating therapies at the 22nd Annual WORLDSymposium 2026, presenting four datasets that demonstrate the potential of its J-Brain Cargo® platform technology to address the neurological manifestations of lysosomal storage disorders (搜索).
The presentations highlighted data from two key programs: preclinical results for JR-471 in fucosidosis (搜索) and long-term clinical outcomes for pabinafusp alfa (IZCARGO™) in mucopolysaccharidosis type II (搜索) (MPS II), also known as Hunter syndrome (搜索).
Breakthrough Preclinical Results for Fucosidosis Treatment
Researchers presented preclinical data on JR-471, a fusion protein combining anti-human transferrin receptor (搜索) 1 antibody with human α-L-fucosidase (搜索) designed to cross the blood-brain barrier through receptor-mediated transcytosis. In a 26-week study using human TfR knock-in and FUCA1 knockout mice, JR-471 demonstrated remarkable efficacy.
The treatment reduced accumulated Fuc-GlcNAc-Asn substrates by more than 95% at maximum levels in both central nervous system tissues, including the brain and cerebrospinal fluid, and peripheral tissues. Researchers observed a strong positive linear correlation between substrate concentrations in the brain and cerebrospinal fluid, validating the biomarker approach.
Critically, JR-471 treatment prevented the loss of Purkinje cells in the cerebellum and preserved motor coordination and learning/memory functions as measured by rotarod and active avoidance tests. "JR-471 may be a promising candidate for the treatment of fucosidosis (搜索) due to its ability to cross the BBB, reduce accumulated substrate in central and peripheral organs, and limit the decline in motor coordination and learning/memory functions," researchers concluded.
Long-Term Clinical Benefits in Hunter Syndrome
Three presentations provided comprehensive evidence for pabinafusp alfa's sustained efficacy in MPS II patients. In a longitudinal analysis of 60 patients across five open-label trials, researchers demonstrated sustained cognitive and adaptive behavior improvements with long-term treatment.
The study included 18 patients with attenuated disease (mean age 20.8 years) and 42 with severe disease (mean age 7.4 years). Cognitive improvements were observed in patients with severe disease who had baseline developmental quotients ≥55 and in patients with attenuated disease, with BSID-III mean changes from baseline to Week 260 of +14.7 and +2.5, respectively.
Adaptive behavior outcomes showed similar positive trends, with VABS-II total raw mean changes from baseline to Week 260 of +152 in severe patients with higher baseline developmental quotients and +33 in attenuated patients, with improvements noted across all VABS-II subdomains.
Somatic Efficacy Across Diverse Patient Populations
A separate analysis of 65 MPS II patients demonstrated pabinafusp alfa's somatic benefits across different age groups and disease phenotypes. In treatment-naïve patients, serum dermatan sulfate and heparan sulfate levels rapidly decreased following treatment, with geometric mean changes from baseline at Week 104 of -65% and -77%, respectively.
Treatment-naïve patients also showed significant reductions in liver and spleen volumes (geometric mean changes from baseline at Week 104: -32% and -39%, respectively) and stabilization of left ventricular mass index by Week 52. Previously treated patients maintained stable biomarker levels and showed decreasing trends in organ volumes.
Flexible Administration Protocols
A pharmacodynamic analysis of 27 Japanese patients over 260 weeks revealed that shorter infusion durations did not compromise safety or efficacy. Patients receiving "fast" infusions (>33 mL/h for ≥66% of infusions) showed similar changes in substrate concentrations and organ volumes compared to those receiving "slow" infusions, with no increase in infusion-associated reactions.
Addressing Critical Unmet Medical Needs
"Lysosomal storage disorders (搜索) are a group of rare diseases that have been notoriously difficult to treat due to the inability to deliver a therapy across the blood-brain barrier into the central nervous system," said Shin Ashida, Chairman, President and CEO of JCR Pharmaceuticals (搜索). "With our J-Brain Cargo® platform technology, we have the potential to address the progressive neurological symptoms associated with these devastating and life-limiting diseases."
The J-Brain Cargo® platform represents a significant advancement in treating lysosomal storage disorders (搜索), which affect an estimated 2,000-3,000 individuals worldwide with Hunter syndrome (搜索) alone. Fucosidosis (搜索) is even rarer, with fewer than 120 cases reported globally and no approved therapies currently available.
Pabinafusp alfa received approval from Japan's Ministry of Health, Labour and Welfare in March 2021 and has been marketed as IZCARGO™ since May 2021. JR-471 remains in preclinical development in partnership with MEDIPAL HOLDINGS CORPORATION (搜索).
The data presented at WORLDSymposium 2026 reinforces the potential of JCR's proprietary blood-brain barrier technology to transform treatment paradigms for rare neurological diseases where traditional enzyme replacement therapies have been limited by their inability to reach the central nervous system.